Pemetrexed in pancreatic cancer

Seminars in Oncology

Volumn 29, Issue 6 SUPPL. 18, 2002, Pages 49-53

  Kindler, Hedy Lee ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYANOCOBALAMIN; DEXAMETHASONE; DIHYDROFOLATE REDUCTASE; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONIST; GEMCITABINE; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; THYMIDYLATE SYNTHASE;

ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; FATIGUE; HUMAN; MUCOSA INFLAMMATION; NEUTROPENIA; PANCREAS CANCER; PRIORITY JOURNAL; RASH; REVIEW; THROMBOCYTOPENIA; VITAMIN SUPPLEMENTATION;

EID: 0036981180     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.37472     Document Type: Review

References (19)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer statistics 2001. CA Cancer J Clin 51:15-36, 2001
2. van Riel JM, Giaccone G, Pinedo HM: Pancreaticobiliary cancer: The future aspects of medical oncology. Ann Oncol 10:S296-S299, 1999 (suppl 4)
3. Rothenberg ML: New developments in chemotherapy for patients with advanced pancreatic cancer. Oncology 10:18-22, 1996 (suppl 9)
4. Casper ES, Green MR, Kelsen DP, et al: Phase II trial of gemcitabine (2′2′ difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 10:29-34, 1994
5. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
6. Heinemann V: Gemcitabine: Progress in the treatment of pancreatic cancer. Oncology 60:8-18, 2001
7. Kroep JR, Pinedo HM, van Groeningen CJ, et al: Experimental drugs and drug combinations in pancreatic cancer. Ann Oncol 10:S234-S238, 1999 (suppl 4)
8. Taylor EC, Kuhnt D, Shih C, et al: A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl) ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 35:4450-4454, 1992
9. Mendelsohn LG, Shih C, Chen VJ, et al: Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 26:42-47, 1999 (suppl 6)
10. Shih C, Chen VJ, Gossett LS, et al: LY231514 a pyrrlo[2,3-d]pyrimidine based antifolate that inhibits multiple folate requiring enzymes. Cancer Res 57:1116-1123, 1997
11. Britten CD, Izbicka E, Hilsenbeck S, et al: Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay. Cancer Chemother Pharmacol 44:105-110, 1999
12. Rinaldi DA, Kuhn JG, Burris HA, et al: A phase I evaluation of multitargeted antifolate (MTA, LY231514) administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 44:372-380, 1999
13. Miller KD, Picus J, Blanke C, et al: Phase II study of the multitargeted antifolate LY231514 (AL1MTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol 11:101-103, 2000
14. Worzalla JF, Shih C, Schultz RM: Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514. Anticancer Res 18:3235-3239, 1998
15. Bunn P, Paoletti P, Niyikiza C, et al: Vitamin B12 and folate reduce toxicity of Alimta (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite. Proc Am Soc Clin Oncol 20:76a, 2001 (abstr 300)
16. Adjei AA: Combination studies with multitargeted antifolate LY231514, MTA, and gemcitabine in advanced solid tumors. Cancer Invest 18:102-103, 2000 (suppl 1) (abstr 79)
17. Adjei AA, Erlichman C, Sloan JA, et al: Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 18:1748-1757, 2000
18. Tonkinson JL, Worzalla JF, Teng CH, et al: Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 59:3671-3676, 1999
19. Kindler HL, Dugan W, Hochster H, et al: Clinical outcome in patients with advanced pancreatic cancer treated with pemetrexed/gemcitabine. Proc Am Soc Clin Oncol 21:125a, 2002 (abstr 499)